Navigation Links
Pharmaxis in Medical News

Pharmaxis Announces NDA Filing for Aridol(TM) (Mannitol Bronchial Challenge Test)

.../ -- Pharmaxis, Inc., a wholly owned subsidiary of pharmaxis Ltd (ASX: PXS, Nasdaq: PXSL ), an emerging respi... Brett Charlton MBBS, PhD, Medical Director, pharmaxis Ltd, added, "Aridol is designed to measure bronchi... of elite athletes who are asthmatic. About pharmaxis ...

Pharmaxis to Expand Manufacturing Capacity

...nchitol to approximately 40,000 patients per year. pharmaxis is developing Bronchitol for the treatment of dise...pand initial capacity in a modular fashion. About pharmaxis pharmaxis (ACN 082 811 630) is a pharmaceutical company invo...
Pharmaxis in Medical Technology

ASX/NASDAQ Media Release: Pharmaxis Files First Marketing Application for Bronchitol in Australia

SYDNEY, Australia, Sept. 30 /Xinhua-PRNewswire-FirstCall/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that a marketing application for the mucus clearing agent, Bronchitol, has been submitted to the Therapeutic Goods Administration (TGA) division of the Austral...

Pharmaxis Announces Positive Results of Phase 3 Cystic Fibrosis Trial

...Newswire-Asia-FirstCall/ -- Pharmaceutical company pharmaxis (ASX: PXS; Nasdaq: PXSL ) is pleased to announce... averages 1-2% per year. Dr Alan Robertson, pharmaxis Chief Executive Officer said: "We are delighted th...treating cystic fibrosis in Europe and elsewhere. pharmaxis will now move to file a marketing application late...

Pharmaxis Announces Milestone in Phase III Trial for Cystic Fibrosis

...le with cystic fibrosis. Dr Alan Robertson, pharmaxis Chief Executive Officer said: "We are very pleased to announce this major milestone for pharmaxis and look forward to the results of the study with ... Bronchitol in people with cystic fibrosis. pharmaxis has received Orphan Drug Designation and fast trac...

Pharmaxis Announces New Drug Application Submission for Aridol(TM)

...Newswire-Asia-FirstCall/ -- Pharmaceutical company pharmaxis (ASX: PXS, Nasdaq: PXSL ) today announced it had... The NDA application is the vehicle through which pharmaxis formally proposes that the FDA approve a new pharm...es complete and ready to use. Alan Robertson, pharmaxis Chief Executive Officer said: "We are delighted to...

Second Pivotal Phase 3 Trial In Cystic Fibrosis Begins

...ua-PRNewswire-FirstCall/ -- Pharmaceutical company pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that it h...chitol for cystic fibrosis in the United States. pharmaxis Chief Executive Officer Dr Alan Robertson said: "W...com.au/library/2008_09_04_CF302_Commences.pdf . pharmaxis is developing Bronchitol as a treatment to improve...

12 Month Phase 3 Trial Finds Bronchitol Safe in Bronchiectasis

...ua-PRNewswire-FirstCall/ -- Pharmaceutical company pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced that the ...es were a consequence of the underlying disease. pharmaxis CEO Alan Robertson said: "Pharmaxis intends to fil...rmaceutical markets suffer from bronchiectasis and pharmaxis expects Bronchitol to be the first targeted medica...

Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment

...baseline in FEV1 (forced expiratory volume in one second) after 26 weeks. pharmaxis Chief Executive Officer Alan Robertson said: "It is rewarding to reach this...esults helping to shape cystic fibrosis clinical practice in the future." pharmaxis has received Orphan Drug Designation and fast track status from the U.S. Fo...

Bronchitol Cystic Fibrosis Dose Trial Results Positive

...re-FirstCall/ -- Speciality pharmaceutical company pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced results f...% on 240 mg, +1.5% on 120 mg and -0.6% on 40 mg. pharmaxis Chief Executive Officer Alan Robertson said, "The ...per year during their life, as measured by FEV1. pharmaxis has received Orphan Drug Designation and fast trac...

Pharmaxis Concludes Special Protocol Assessment with FDA for Bronchitol Phase 3 Trial

... and/or data analyses are acceptable to the FDA. pharmaxis previously agreed on the trial design with the Eur...f a successful shorter trial reported last year. pharmaxis CEO, Alan Robertson, said the company was pleased ...l trial is expected to soon close recruitment.'' pharmaxis is developing Bronchitol as a treatment to improve...

Pharmaxis Establishes Named Patient Program for Bronchitol

... The program will allow patients who are unable to participate in current pharmaxis clinical trials but who are considered by their physician to be suffering f... to medicines in countries where the product is yet to be authorised," said pharmaxis CEO Alan Robertson. "Bronchitol will be made available to people with a c...
Pharmaxis in Biological Technology

New Pharmaxis Board Appointment

SYDNEY, April 6 /PRNewswire-Asia/ -- Pharmaceutical company Pharmaxis (ASX: PXS; Nasdaq: PXSL ) today announced the appointment of the U.S. life science investment manager Richard van den Broek to its Board of Directors. Mr van den Broek is founder and managing partner of HSMR Advisor...

New Pharmaxis Board Appointment

SYDNEY, Australia, June 23 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis (ASX: PXS; Nasdaq: PXSL) today announced the appointment of senior Australian pharmaceutical executive Will Delaat to its board of directors. Mr Delaat has 35 years experience in the global pharmaceutical industry, most re...

Pharmaxis Investor Conference Call

... SYDNEY, July 21 /PRNewswire-Asia/ -- pharmaxis Ltd (ASX: PXS) will release its June 2009 Quarterl...cording of the conference will be available on the pharmaxis website home page approximately 3 hours after the call. CONTACT: pharmaxis Investor Relations Tel: +61-2-9454-7200 ...

Pharmaxis to Voluntarily De-List from Nasdaq

... SYDNEY, July 12 /PRNewswire-Asia/ -- pharmaxis (ASX: PXS; Nasdaq: PXSL ) today announced a deci...t from the Nasdaq Global Market ("Nasdaq"). pharmaxis has recently completed a review of the demand from...itary Shares ("ADS's") on Nasdaq and the volume of pharmaxis ADS trading in the secondary Nasdaq market. The r...

Pharmaxis Closes Share Purchase Plan

... SYDNEY, June 29 /PRNewswire-Asia/ -- pharmaxis (ASX: PXS; Nasdaq: PXSL ) today announced it had raised A$7.2 million fro...ximately $7.2 million. Dr Alan Robertson, Chief Executive Officer of pharmaxis said, "We are very encouraged and appreciative of the level of support from...

Pharmaxis Announces Placement of $47 Million and Share Purchase Plan

... SYDNEY, June 3 /PRNewswire-Asia/ -- pharmaxis (ASX: PXS, Nasdaq: PXSL ) today announced that i...acement strengthens the company's balance sheet as pharmaxis moves toward the European and U.S. commercial laun...its product Bronchitol for cystic fibrosis. pharmaxis will issue 20 million new fully paid ordinary shar...

U.S. FDA Accepts Aridol(TM) New Drug Application for Review

... SYDNEY, Australia, May 13 /PRNewswire-Asia/ -- pharmaxis (ASX: PXS; Nasdaq: PXSL ) today announced it had...e result of the review on 27 December 2009. pharmaxis is seeking approval for Aridol for "the assessment... test available in the U.S. Alan Robertson, pharmaxis Chief Executive Officer said: "We have been greatl...

Pharmaxis Investor Conference Call

... SYDNEY, Australia, April 6 /PRNewswire-Asia/ -- pharmaxis Ltd (AXS: PXS; Nasdaq: PXSL ) will release its M...cording of the conference will be available on the pharmaxis website home page approximately 3 hours after the call. CONTACT: pharmaxis Investor Relations Tel: +61-2-9454-7200 ...

Pharmaxis Appoints French Distributor for Aridol(TM)

... SYDNEY, March 11 /PRNewswire-Asia/ -- pharmaxis (ASX: PXS; NASDAQ: PXSL ) is pleased to announce that it has appointed Pr...after market the product to hospital specialists. Dr Alan Robertson, pharmaxis CEO said "We are delighted to announce this agreement and are looking forwa...

Pharmaxis Builds Senior Management Team

...cal Expert for Novartis. Dr Alan Robertson, pharmaxis Chief Executive Officer said: "The appointment of ...ory and pharmacovigilance experience necessary for pharmaxis to bring Bronchitol successfully and rapidly to th...the company's head office in Sydney. About pharmaxis ...
Other Tags
(Date:9/22/2014)... September 22, 2014 WHO: LiveOps, ... and customer service solutions. , WHAT: The 10th ... on customer care for the connected consumer. Constant ... to offer new challenges and opportunities for customer ... attendees identify best practices, network and learn from ...
(Date:9/22/2014)... Metformin, a drug commonly used to treat diabetes, may ... (TSH) among patients with an underactive thyroid, a new ... levels may be associated with heart problems and broken ... this study. Among those in the study with ... low levels of thyroid-stimulating hormone per year compared with ...
(Date:9/22/2014)... Tara Haelle ... News) -- Measuring how quickly a child,s brain processes ... to a new study. Observing children,s brainwaves ... currently possible, the study authors reported. "The finding ... is associated with autism severity is hugely promising," said ...
(Date:9/22/2014)... September 22, 2014 The “ Ztylus ” ... Tech Report , which reviews and features the latest technology ... of NewsWatch and technology expert, conducted the review and shared ... snap-in lens kit that gives users four lens options for ... part of its monthly Tech Report, which reviews and features ...
(Date:9/22/2014)... Medical experts this past weekend gathered ... discuss brain-related diseases facing an aging population, including ... disorders. , Each of the 50 attendees ... memory care community or hospice office. Silverado, with ... hosts the annual event to facilitate the exchange ...
Breaking Medicine News(10 mins):Health News:LiveOps To Lead Panel Discussion At Customer Response Summit Memphis 2Health News:Diabetes Drug Metformin May Affect Thyroid in Some Patients 2Health News:Brainwaves May Help Gauge Autism Severity: Study 2Health News:Brainwaves May Help Gauge Autism Severity: Study 3Health News:Brainwaves May Help Gauge Autism Severity: Study 4Health News:NewsWatch Recently Featured the Phone Case “Ztylus” on National Television 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 2Health News:Nation’s Leading Brain Health Experts Gather for Annual Silverado Medical Director Conference 3
(Date:9/19/2014)... A University of Oklahoma biology professor will study ... control leg movements with a National Science Foundation ... four-year project. , Ari Berkowitz, professor in the ... Sciences, will focus on the differences between the ... understand what neurotransmitters they use and what connections ...
(Date:9/18/2014)... developed a unique method to use microbes buried in ... , The first microbe-powered, self-sustaining wastewater treatment system ... clean up waste from large farming operations and rural ... Haluk Beyenal and graduate student Timothy Ewing in the ... in the online edition of Journal of Power ...
(Date:9/18/2014)... system that can operate inside the bore of an ... a biomedical research partnership program at Brigham and Women,s ... the robot, in conjunction with real-time MRI images, can ... and less discomforting for the patient. The novel system ... with greater precision. , Developed by a team of ...
Breaking Biology News(10 mins):Researchers develop unique waste cleanup for rural areas 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 2Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 3Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 4Trial begins for MRI-compatible robot designed to improve accuracy of prostate biopsies 5
Other Contents